Solara Active Pharma Sciences: Monitoring Agency Report for Q2 FY27

Solara Active Pharma Sciences Ltd has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. The report, issued by CRISIL Ratings Limited, confirms the utilization of proceeds from the company's Rights Issue. Solara Active Pharma Sciences confirms that there has been no deviation or variation in the utilization of Issue proceeds from the objects stated in the Letter of Offer for the Rights Issue. CRISIL Ratings Limited, as the appointed Monitoring Agency, has provided its report as per SEBI regulations, stating no deviation from the objects.